Prognostic factor analysis in 325 patients with Graves' disease treated with radioiodine therapy
- PMID: 29040161
- PMCID: PMC5728590
- DOI: 10.1097/MNM.0000000000000770
Prognostic factor analysis in 325 patients with Graves' disease treated with radioiodine therapy
Abstract
Introduction: I therapy is a choice for Graves' hyperthyroidism. Several factors that affect the success of I treatment in Graves' disease (GD) patients have been put forward. The aim of this retrospective study was to evaluate the factors influencing the success of I therapy and the occurrence of hypothyroidism after I therapy.
Patients and methods: We reviewed 325 GD patients, who were well documented out of 779 cases, treated with I in the First Affiliated Hospital of Xi'an Jiaotong University between 2010 and 2016. We collected the potential influencing factors, including demographic data (age, sex, family history), iodine intake state, antithyroid drugs (ATD) taking, thyroid texture, complications of hyperthyroidism, physical and laboratory examinations [thyroid weight, effective I half-life time (Teff), 24-h iodine uptake rate, tri-iodothyronine, thyroxine, free tri-iodothyronine (FT3), free thyroxine, thyroid-stimulating hormone, thyroglobulin antibody, thyroid microsome antibody, thyrotropin receptor antibody], and final administered dosages according to Quimby formula. The correlations between the prognosis of GD patients and these factors were analyzed by logistic regression analysis.
Results: Out of 325 patients, 247 (76.00%) were treated successfully with radioiodine. GD patients who were cured by I therapy were more likely to have smaller thyroid [odds ratio (OR)=0.988, 95% confidence interval (CI)=0.980-0.996, P=0.002], lower FT4 levels (OR=0.993, 95% CI=0.988-0.997, P=0.002), and shorter time of ATD withdrawal before I treatment (OR=0.985, 95% CI=0.975-0.996, P=0.002). Hypothyroidism occurred in 132 (41.00%) out of 325 patients. There was an increased risk of early hypothyroidism in patients with lower 24-h iodine uptake (OR=0.964, 95% CI=0.941-0.988, P=0.004), and treated with a lower total dose of iodine (OR=0.892, 95% CI=0.824-0.965, P=0.005) and a higher iodine dose per garm of thyroid tissue (OR=5.414E+14, 95% CI=45.495-6.444E+27, P=0.027).
Conclusion: Our results showed that I treatment was more successful in patients with lower weight of the thyroid, lower free thyroxine level, and shorter ATD taking period. Furthermore, early hypothyroidism after radioiodine treatment was more likely to occur in patients with lower 24-h iodine uptake, lower total dose of iodine, and higher iodine dose per garm of thyroid tissue.
Similar articles
-
Radioiodine therapy in Graves' disease patients with large diffuse goiters treated with or without carbimazole at the time of radioiodine therapy.Thyroid. 1999 Dec;9(12):1181-8. doi: 10.1089/thy.1999.9.1181. Thyroid. 1999. PMID: 10646656
-
Predictive factors influencing hypothyroidism following the radioactive iodine treatment of Graves' disease in different periods.Sci Rep. 2024 Dec 28;14(1):31148. doi: 10.1038/s41598-024-82521-5. Sci Rep. 2024. PMID: 39732988 Free PMC article.
-
The effect of propylthiouracil on subsequent radioactive iodine therapy in Graves' disease.Clin Endocrinol (Oxf). 1997 Oct;47(4):425-30. doi: 10.1046/j.1365-2265.1997.2741075.x. Clin Endocrinol (Oxf). 1997. PMID: 9404440
-
Radioactive iodine therapy in Graves' hyperthyroidism.Natl Med J India. 2000 Sep-Oct;13(5):246-51. Natl Med J India. 2000. PMID: 11190053 Review.
-
The tale of radioiodine and Graves' orbitopathy.Thyroid. 2010 Jul;20(7):785-93. doi: 10.1089/thy.2010.1640. Thyroid. 2010. PMID: 20578895 Review.
Cited by
-
Predictive factors for early hypothyroidism following the radioactive iodine therapy in Graves' disease patients.BMC Endocr Disord. 2020 May 29;20(1):76. doi: 10.1186/s12902-020-00557-w. BMC Endocr Disord. 2020. PMID: 32471411 Free PMC article.
-
Predictive Factors for the Efficacy of Radioactive Iodine Treatment of Graves' Disease: An Experience From 613 Chinese Patients.Int J Endocrinol. 2024 Nov 8;2024:7535093. doi: 10.1155/2024/7535093. eCollection 2024. Int J Endocrinol. 2024. PMID: 39555247 Free PMC article.
-
Age moderates the associations between TRAbs, free T3 and outcomes of Graves' disease patients with radioactive iodine treatment.Clin Endocrinol (Oxf). 2021 Feb;94(2):303-309. doi: 10.1111/cen.14301. Epub 2020 Aug 13. Clin Endocrinol (Oxf). 2021. PMID: 32734611 Free PMC article.
-
Radioiodine treatment for graves' disease: a 10-year Australian cohort study.BMC Endocr Disord. 2018 Dec 12;18(1):94. doi: 10.1186/s12902-018-0322-7. BMC Endocr Disord. 2018. PMID: 30541519 Free PMC article.
-
Effects of Trace Elements on Endocrine Function and Pathogenesis of Thyroid Diseases-A Literature Review.Nutrients. 2025 Jan 22;17(3):398. doi: 10.3390/nu17030398. Nutrients. 2025. PMID: 39940256 Free PMC article. Review.
References
-
- Prabhakar BS, Bahn RS, Smith TJ. Current perspective on the pathogenesis of Graves’ disease and ophthalmopathy. Endocr Rev 2003; 24:802–835. - PubMed
-
- Weetman AP. Graves’ disease. N Engl J Med 2000; 343:1236–1248. - PubMed
-
- Zaiying L, Nanshan Z. Internal science, 7th ed Beijing: People’s Health Publishing House; 2008. 591–600.
-
- Bahn Chair RS, Burch HB, Cooper DS, Garber JR, Greenlee MC, Klein I, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid 2011; 21:593–646. - PubMed
-
- Jiang N, Lin Y, Guan H, Tan J, Li L, Gao Z, et al. The guide of 131I therapy for Graves’ hyperthyroidism (2013 edition). Chin J Nucl Med 2013; 33:83–94.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials